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Conventional and composed cyclosporin A (CsA)-loaded polymeric microspheres
(MS) were prepared by spray-drying of CsA/chitosan one-phase system (solutions) and
CsA/lecithin/chitosan two-phase system (suspensions). Microspheres were characterised
in terms of production yield, entrapment efficiency, size distribution, zeta-potential, ther-
mal properties, swelling ability and drug release profile.
Conventional MS were characterised by mean diameter ranging from 1.15 ± 0.91 to
1.27 ± 0.84 m and CsA entrapment efficiency varying from 72.6 to 87.3%. Composed
MS were characterised by larger mean diameter (1.32 ± 1.08 to 1.53 ± 1.15 m) and
higher CsA entrapment efficiency (86.6–94.3%) compared to the corresponding conven-
tional MS. Only composed MS showed swelling ability, which was proportional to
chitosan base content in the preparation. In vitro CsA release profile depended on both,
the type of the spray-dried system and the chitosan used, as these factors were crucial in
determining CsA entrapment pattern and swelling/dissolution ability of MS.
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Introduction
Cyclosporin A (CsA) is highly lipophilic
neutral cyclic peptide consisting of 11 amino acids
of which 7 N-methylated. Its molecular formula
is C62H111N11O12, has a molecular weight of
1202.64 Daltons, and contains four intermolecular
hydrogen bonds that affect the strength of pro-
nounced cyclical structure. Such an unusual struc-
tural properties affect the extremely low solubility
in water (6.6 mg/ml), or extreme hydrophobicity
(logP = 3.0).1 Pursued by poor and erratic bio-
availability from oral, transdermal and ocular
routes, the delivery of CsA is a challenging task and
explains the constant efforts by the pharmaceutical
scientists to design effective delivery systems.1
Although progress has been made, there is still pos-
sibility for improvement in the application of CsA,
as none of these formulations is ideal.2
At concentrations of 50–300 ng/g of ocular tis-
sue, CsA effectively suppresses the immune re-
sponse and inflammation in most ocular disorders.3
Local immunosuppression caused by CsA is effec-
tive for the management of extra ocular disorders.
The target sites for the treatment of these diseases
are the cornea and conjunctiva, and a number of
drug delivery systems for topical CsA delivery in
the eye were investigated so far.4 The local ocular
drug delivery is restricted by the dynamics of the
lachrymal drainage system, which is the natural de-
fense mechanism of the eye. This system introduces
tear fluid to the eye and rapidly drains the fluid to-
gether with any instilled formulation from the
precorneal area to the nasal cavity and throat. The
high elimination rate results in short duration of
contact of the drug with its absorption sites and
consequently in a low local bioavailability. In-
creased ocular bioavailability can be achieved by
the use of viscosity enhanced aqueous eye drops,
suspensions, oily drops and unguents, mucoadhesive
ocular delivery systems such as solutions and
microparticle suspensions, in-situ gelling systems
triggered by pH, temperature, or ions change, col-
loidal delivery systems such as liposomes and
nanoparticles, and ocular inserts.5–11
The aim of this study was the development and
characterisation of ophthalmic drug delivery system
– MS, which depending on size, charge and bio-
adhesive properties, can improve absorption and
bioavailability of CsA. MS as drug delivery system
with large surface to volume ratio can make firm
contact and allow for longer retention of the drug at
the site of application/absorption.
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Chitosan (CS), a polycationic biopolymer is
well known for its several favourable biological
properties such as biodegradability, nontoxicity and
biocompatibility.12 Chitosan increases transepithelial
permeability due to its ability to reversibly disrupt
the epithelial tight junctional complexes up to a pH
of around 6.13,14 These exceptional biological fea-
tures of CS make it an ideal polymer in drug de-
livery systems such as micro- and nanoparticles
intended for topical and ocular drug delivery.15
Chitosan-based colloidal systems were found to
work as transmucosal drug carriers, either facili-
tating the transport of drugs to the inner eye
(chitosan-coated colloidal systems containing
indomethacin) or their accumulation into the cor-
neal/conjunctival epithelia (chitosan nanoparticles
containing CsA).15
Nanocarriers, such as nanoparticles, have the
capacity to deliver ocular drugs to specific target
sites and hold promise to revolutionize the therapy
of many eye diseases. The surface characteristics of
the nanocarriers, among other properties, have an
influence on the interaction with the ocular surface
structures. Chitosan nanoparticles loaded with CsA
can contact intimately with the corneal and con-
junctiva surfaces, thereby increasing delivery to ex-
ternal ocular tissues without compromising inner
ocular structures and systemic drug exposure. This
helps to provide these target tissues with long-term
drug levels.4 CsA was incorporated successfully
into cationic Eudragit RS 100 nanoparticles
(EPNs). In vitro release studies showed the ex-
tended release, and in vivo results demonstrated the
prolonged residence time of CsA in the deeper lay-
ers (vitreous humour) of the eye with positively
charged EPNs.16 Topical ophthalmic efficacy of
CsA was enhanced via administration of solid lipid
nanoparticles (SLNs). 17 In this study, conventional
and composed CsA-loaded MS were prepared by
spray-drying of CsA/chitosan one-phase feeds (so-
lutions) and CsA/lecithin/chitosan two-phase feeds
(suspensions). Microspheres obtained were charac-
terised in terms of production yield, entrapment
efficiency, size distribution, zeta-potential, physical
state of the drug incorporated in the polymer ma-
trix, swelling ability and drug release profile.
Materials and methods
Materials
CsA was obtained from Galena (Czech Re-
public). Chitosan base (CB, Protasan UP Base,
deacetylation degree 84%) and chitosan in the salt
form as chitosan chloride (CS, Protasan UP CL 213,
deacetylation degree 86%) were purchased from
NovaMatrix (Norway). Fat-free soybean lecithin
with 45% phosphatidyl choline (Lipoid S45; LS45)
and phosphatidyl choline from fat-free soybean lec-
ithin (Lipoid S100; LS100) were a kind gift from
Lipoid GmbH (Germany).
Simulated tear fluid (STF) was prepared as an
aqueous solution containing 6.7 g NaCl, 2.0 g
NaHCO3 and 0.08 g CaCl2 × 2H2O per litre. All
other chemicals or solvents used were of analytical
grade and purchased from Kemika (Croatia).
Preparation of CsA loaded MS
MS were prepared by spray-drying method, us-
ing a Mini Spray Dryer Büchi 190 (Flawil, Switzer-
land) with a standard 0.5 mm nozzle. The drying
conditions were as follows: dry air rate of 700 NL/h;
inlet air temperature of 157 °C, outlet air tempera-
ture of 81 °C and feed pump rate of 0.25 L/h. The
resulting dried products were collected and kept
away from rehydration until further tests.
Lecithin (LS45 or LS100) was dissolved in
96% ethanol at a concentration of 0.4% (w/v).
Chitosan chloride (CS) was solubilised in distilled
water at a concentration of 2% (w/v). Chitosan base
(CB) was solubilised in 0,5% acetic acid at a con-
centration of 2% (w/v). CB solution and CS solu-
tion were mixed (CB/CS), obtaining a CB-to-CS
weight ratio of 3:2. For the preparation of CsA-loaded
chitosan MS, CsA was dissolved in 96% ethanol at
a concentration of 0.13% (w/v). For the preparation
of CsA-loaded chitosan/lecithin MS, CsA was dis-
solved in the ethanolic solution of lecithin at a
concentration of 0.13% (w/v), obtaining a leci-
thin-to-CsA weight ratio of 3:1.
Feed dispersions were obtained as follows:
22.5 ml of ethanolic CsA or lecithin/CsA solution
was injected (syringe inner diameter of 0.75 mm)
into 35 ml of distilled water that was magnetically
stirred (900 rpm). Appropriate volume of CB, CS
or CB/CS solution was then injected to CsA or leci-
thin/CsA suspension magnetically stirred in order to
obtain CsA/chitosan ratio of 1:9. Prepared disper-
sions were subjected to spray-drying under process
conditions described above. CsA-free (empty) MS
were prepared following the same procedure as for
CsA-loaded MS.
In vitro characterization of MS
Evaluation of entrapment efficiency and yield of MS
The CsA content in MS was determined di-
rectly by measuring the encapsulated CsA amount
in MS. A known weight of spray-dried powder was
dissolved in 96% ethanol, magnetically stirred
(300 rpm) for 24 h, and put for 1 h in an ultrasonic
bath. After centrifugation for 30 min at 3,000 rpm,
supernatant was filtered and evaporated to dryness
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and subsequently dissolved in 30 ml of aceto-
nitrile:water (1:1 v/v) mixture. The CsA content of
the samples was determined by HPLC (Shimadzu
LC-10 Series). A Nucleosil 100-5-C-18 column
(5 m, 4x125 mm, Agilent, USA) was used. The in-
jection volume was 20 l. The mobile phase con-
sisted of phosphoric acid/1,1-dimethylethyl methyl
ether/acetonitrile/water (1/50/430/20) mixture. The
detector wavelength, flow rate, and column temper-
ature were 210 nm, 1.5 mL/min and 80 °C respec-
tively. This method is described in CsA Monograph
in European Pharmacopoeia.
Entrapment efficiency of the CsA (1) and the
yield of MS (2) were calculated according to the
following equations:
EE = (Weight of drug determined (mg) /
/ Weight of drug added (mg)) x 100 (1)
Yield = (The total weight of obtained MS (mg) /
/ drug+polymer weight (mg)) × 100 (2)
MS size and zeta potential analyses
A microscopic imaging analysis technique for
determination of MS size distribution was applied.
MS morphology and size distribution were deter-
mined with an Olympus BH-2 microscope equipped
with a camera (CCD Camera ICD-42E, Ikegami
Tsushinki Co., Japan) and a computer-controlled
image analysis system (Optomax V, Cambridge).
The MS were dispersed on a microscope slide. A
microscopic field is scanned by video camera. The
images of the scanned fields are digitalised and ana-
lysed by the software to determine MS equivalent
spherical diameter (ESD) from area and particle
size distribution. In all measurements at least 1500
particles were examined.
The zeta potential of the particles was deter-
mined using Photon Correlation Spectroscopy with
a Zetasizer 3000 (Malvern Instruments, Malvern,
UK) in 10 mM NaCl solution (pH 6.7) at 25 °C.
The analyses were performed in triplicate.
MS swelling analyses
The water-absorbing capacity of MS was deter-
mined by a volumetric method using a Franz diffu-
sion cells at room temperature. A water-permeable
polyamide membrane with 0.45 m pore size was
placed between the donor compartment with MS
(3 mg) and receptor compartment, which was filled
with STF. The level of STF in graduated part of
Franz diffusion cell lowered due to liquid uptake of
the MS. The amount of STF, equal to the amount of
STF absorbed by the MS was then added to the re-
ceptor compartment. The liquid uptake of each MS
sample was expressed as volume of STF added per
milligram of the MS in 15 min swelling process.
Modulated differential scanning calorimetry (MDSC)
Modulated differential scanning calorimetry
(MDSC) analyses were performed on a TA Instru-
ment Q1000 Modulated DSC (TA Instruments, New
Castle, DE, USA) using aluminium hermetic pans
with pierced lids to allow for removal of residual
solvent, with approximately 5 ± 2 mg sample, under
a dynamic nitrogen atmosphere (50 ml/min). Sam-
ples were heated at 5 °C/min from 20 °C to 180 °C
using a modulation temperature amplitude of ± 0.8 °C
and period of 60 s. The glass transition temperature
(Tg) was determined using the TA Universal Analy-
ses 2000 Software by extrapolating the linear por-
tion of the DSC curve above and below the glass
transition point and determining the midpoint tem-
perature in the reverse heat flow curve. The analy-
ses were performed in triplicate.
In vitro release studies
Drug release was determined as follows: CsA
loaded MS (3 mg) were placed in glass beaker
filled with STF (20 mL) maintained in gentle agita-
tion by means of a magnetic stirrer (600 rpm). At
scheduled time intervals, the filtered (pore size
0.45 m) samples (0.5 ml) were withdrawn from
the beaker and replaced with the fresh medium. The
drug content in the samples was quantified by the
HPLC method described previously. The analyses
were performed in triplicate.
Statistical analysis
Statistical data analyses were performed on all
data by a one-way ANOVA followed by multi-para-
metric Tukey’s post hoc test with p<0.05 as the
minimal level of significance. Calculations were
performed with the GraphPad Prism program
(GraphPad Software Inc., San Diego, USA;
www.graphpad.com).
Results and discussion
Preparation of CsA loaded MS
Chitosan MS were prepared by spray-drying
from CsA/chitosan solution or CsA/lecithin/chito-
san suspension.
Thermal efficiency of the spray-drying method
depends on the input of heat energy (inlet tempera-
ture) and the amount of heat used in the process of
evaporation. The optimal efficiency of spray-drying
method can be achieved by balancing the amount of
input energy and the amount of energy needed, de-
pending on the sample volume to be sprayed. When
the solvent is water inlet air temperature must be
higher than 100 °C. It was found that the inlet air
temperature to produce chitosan MS from chitosan
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aqueous solution should be around 160 °C. If the
inlet air temperature is lower than 140 °C, or the
sample flow rate is greater than 10 ml/min, the sol-
vent from the droplets cannot completely evaporate
and droplets adopt the inner wall of the main cham-
ber of the spray-drier18.
In this study, the preliminary investigations have
determined conditions under which dry, non-ag-
glomerated MS were obtained, and at which the
highest production yields were achieved (standard-
ized conditions).
Chitosan and lecithin were selected as drug
carriers in the preparation of CsA-loaded MS be-
cause of their natural origin, biocompatibility and
biodegradability. Two types of chitosan (chitosan
base (CB) and chitosan chloride (CS)) and their
mixtures (CB/CS 3:2, w/w) were used.
Used chitosans differ in solubility, degree of
deacetylation and viscosity (Table 2). Chitosan as a
base (pKa  6.5) is insoluble in neutral and alka-
line medium, while the organic and inorganic
chitosan salts, like chitosan chloride used in this
study, are well soluble in water. Two types of soy-
bean lecithin, LS45 and LS100 were used for the
preparation of MS, differing in components that
contribute to a negative charge. LS45 contains more
components that contribute to the negative charge
than LS100 and is therefore more negatively
charged. The intensity of interaction of lecithin
with the positively charged chitosan affects the de-
gree of compaction of MS. All prepared MS have
the same weight ratio of CsA, lecithin and chitosan,
which is 1:3:9 respectively.
The single-phase systems (solutions) were pre-
pared by dissolving CsA in ethanolic chitosan solu-
tion and two-phase systems (suspensions) were pre-
pared by dispersing ethanolic CsA/lecithin solution
in aqueous chitosan solution, and were subjected to
spray-drying to obtain MS. Specifically, injection
of ethanol solution of CsA/lecithin and viscous so-
lution of chitosan in the water resulted in the forma-
tion of CsA-loaded lecithin vesicles suspended in
the aqueous solution of chitosan. The interaction
between the negatively charged components on the
lecithin vesicles surface and positively charged
amino groups of chitosan is assumed. Electrostatic
interactions between lecithin and chitosan have
been extensively described in the literature.19,20
Chitosan/lecithin nanoparticles can occur due to the
self-assembly of lecithin molecules and chitosan
due to ionic interactions.19 The structure of
nanoparticles was studied by combining various an-
alytical methods such as cryo-TEM, dynamic light
scattering (DLS) and small angle neutron scattering
(SANS).20 Chitosan/lecithin nanoparticles are posi-
tively charged. The charge depends on the type of
lecithin and the mass ratio of chitosan and lecithin
in the formulation.21 Because of the positive charge
chitosan/lecithin nanoparticles electrostatically re-
act with negatively charged mucin and mucosal
components, which reduces mucociliary clearance
of nanoparticles.21
In vitro characterization of MS
The entrapment efficiency and yield of MS
The preparation yields obtained are relatively
high with respect to the applied method and ranged
from 46.7 ± 5.2 to 57.3 ± 5.5%. Losses in the pro-
cess of spray-drying are the result of sample adhe-
sion to the cylinder wall. Also the lightest and
smallest particles together with the air leave the
spray-drier because there is no filter that would
keep them in the system.
MS preparation yields of single-phase sprayed
systems (CsA-loaded chitosan MS) were not signif-
icantly different from the MS yields obtained by
spray-drying of two-phase systems (CsA-loaded
chitosan/lecithin MS). Two-phase systems, as op-
posed to single-phase systems, in their composition
contain both chitosan and lecithin. It can be con-
cluded that the introduction of lecithin in the feed
composition of the MS did not affect the utilization
of their preparation.
Two types of chitosan solutions used for the
preparation of feed dispersions were of equal con-
centration but different viscosities (Table 1), which
may affect the utilization of the preparation. The
feeds of higher concentration and/or viscosity are of
the slower flow at the same drying conditions, caus-
ing the drying air is less saturated with the evapo-
rated solvent, enhanced particles drying, and less
adhesion of particles on cylinder wall of the
spry-drier.22 The results however show that type of
chitosan used in the preparation of sprayed systems
did not affect the MS preparation yields. It can be
concluded that the feeds were not significantly dif-
ferent in viscosity due to multiple dilution of stock
chitosan solutions and the presence of ethanol.
The CsA entrapment efficiency of MS was de-
termined after destruction of the known weight of
MS in absolute ethanol. EE ranged between 72.6
and 94.3% (Table 1).
The CsA entrapment of MS spray-dried from
two-phase feeds is significantly higher compared to
the corresponding MS obtained by spray-drying of
single-phase feeds. The single-phase spray-dried
feeds resulted with CsA-loaded chitosan MS and
lipophilic drug being dispersed in a hydrophilic
polymer matrix. On the other hand, by spray-drying
of the two-phase systems chitosan MS with
CsA-loaded lecithin nanoparticles were formed.
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Lecithin introduction into the system advanced the
encapsulation of lipophilic CsA in chitosan MS.
Given the entrapment efficiency of CsA, MS
prepared with LS45 did not significantly differ
from the corresponding MS prepared with LS100.
For example, EE of CsA in BLS100 and BLS45
MS was 87.8 ± 0.8 and 86.6 ± 0.3% respectively.
Also, the SLS100 and SLS45 MS were observed
with 94.3 ± 1.3 and 91.5 ± 2.0% CsA EE, respec-
tively.
The size and zeta-potential of MS
The MS were of satisfactory size distribution
with about 95% particles with diameter smaller
than 5 m and with mean diameter in the range of
1.15 ± 0.91 to 1.53 ± 1.15 m (Table 1). The mean
diameter of MS prepared by spray-drying of sin-
gle-phase feeds (CsA-loaded chitosan MS), is in the
range of 1.15 ± 0.91 to 1.27 ± 0.84 m, with 85%
particles smaller than 2 m, and is smaller than the
mean diameter of corresponding MS prepared by
spray-drying of two-phase feeds (CsA-loaded
chitosan/lecithin MS) ranged between 1.32 ± 1.08
and 1.53 ± 1.15 m, with only 65–70% particles
smaller than 2 m.
The CsA-loaded chitosan/lechitin MS prepared
with LS45 were bigger than the corresponding MS
prepared with LS100 (Table 1). It is assumed that
the size of the MS depended on the strength of in-
teraction between chitosan and lecithin. Since the
LS45 has more negative charge than LS100, its in-
teraction with the positively charged amino groups
of chitosan is stronger, resulting in the formation of
slightly larger particles.
Two types of chitosan solution used for the MS
preparation were of equal concentration but of dif-
ferent viscosities (Table 1) that could affect the size
of the prepared MS. However, given the multiple
dilution of chitosan stock solutions and the pres-
ence of ethanol in sprayed feeds, they did not sig-
nificantly differ in viscosity and thus corresponding
MS prepared with different types of chitosan solu-
tion were not significantly different in size. For ex-
ample, mean diameters of conventional CsA-loaded
chitosan MS, prepared from the solution of chitosan
base, chitosan chloride, or their mixture (CB:CS
3:2, m/m), were 1.21 ± 0.93, 1.27 ± 0.84 and
1.15 ± 0.91 m, respectively.
Zeta-potential of MS was measured after the
dispersion of MS in 10 mM NaCl solution (pH 6.7,
temp. 25 °C). The results are shown in Figure 1.
The zeta-potential of LS45 and LS100 nanoparticles
was –11.0 ± 0.8 and –39.5 ± 1.2 mV, respectively.
The negative charge is a consequence of dissocia-
tion of functional groups of the components of leci-
thin.
All chitosan MS were characterized by a po-
sitive zeta-potential in the range of 21.9 ± 1.1 to
49.1 ± 0.8 mV. The positive charge on the surface
of the MS derived from the positively charged
amino groups of chitosan. Zeta-potential of conven-
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B BLS100 BLS45 S SLS100 SLS45 BS BSLS100 BSLS45
Lecithin type – LS100 LS45 – LS100 LS45 – LS100 LS45
Yield (%) 57.3 ± 5.5 54.3 ± 7.3 52.0 ± 5.1 46.7 ± 5.2 48.5 ± 3.2 48.7 ± 3.5 47.5 ± 2.4 53.9 ± 0.5 49.1 ± 4.2
Drug content (%) 7.2 ± 0.06 6.6 ± 0.02 6.6 ± 0.02 8.7 ± 0.03 7.2 ± 0.14 6.9 ± 0.04 7.3 ± 0.02 7.0 ± 0.01 6.5 ± 0.02
EE (%) 72.6 ± 0.7 87.8 ± 0.8 86.6 ± 0.3 87.3 ± 1.3 94.3 ± 1.3 91.5 ± 2.0 73.3 ± 1.0 91.3 ± 0.8 86.7 ± 0.3
Mean diameter
(m)
1.21 ± 0.93 1.32 ± 1.08 1.53 ± 1.15 1.27 ± 0.84 1.38 ± 1.13 1.44 ± 1.17 1.15 ± 0.91 1.15 ± 0.91 1.51 ± 1.08
VSTF (l/mg) 0 51.7 ± 1.7 48.3 ± 1.7 0 0 0 0 23.3 ± 0 20.0 ± 0
F i g . 1 – The zeta-potential of chitosan and chitosan/lecithin
microspheres prepared with chitosan base (CB), chitosan chlo-
ride (CS) and their mixture (CB+CS) in weight ratio of 3:2,
and lecithins LS100 and LS45. Values are mean ± SD (n=3).
tional MS increased, depending on the type of
chitosan used in their preparation, in the following
sequence: CB < CB+CS < CS. Higher values of the
zeta-potential of chitosan chloride microspheres
(24.9 mV) than the zeta potential of chitosan base
microspheres (9.7 mV) were observed earlier.18
Effect of lecithin on the zeta-potential of com-
posed MS was in line with observations for conven-
tional MS (CB < CB+CS < CS). Thus, the zeta-po-
tential of composed MS prepared with CS (SLS100
and SLS45) was about 8 mV lower than the
zeta-potential of corresponding conventional MS
(S), while the difference in zeta-potential between
composed and conventional MS prepared with CB
was within the standard deviation. This is probably
due to different solubility of CB and CS.
Swelling of MS
Swelling of MS was expressed as the volume
of artificial tear fluid absorbed by the 1 mg of MS
over time (Table 1). In contact with the artificial
tear fluid MS, depending on their composition,
swelled (composed MS prepared with CB or
CB+CS), dissolved (composed MS prepared with
CS) or remained unchanged (conventional MS).
The CS dissolves in contact with aqueous media
while CB swells. In the absence of contact of poly-
mer with the aqueous media MS remain unchanged.
Conventional MS behaved like that. The less EE of
lipophilic CsA into conventional MS, and its pres-
ence at the MS surface prevented contact of MS
with aqueous medium and chitosan from swelling.
Swelling and dissolution was observed for com-
posed MS. Lecithin improved integration of
lipophilic CsA in composed MS and thereby re-
duced its presence on the surface of MS, as well as
it reduced contact angle and improved MS wetting.
Swelling of MS, except the presence of leci-
thin, depended on the proportion of CB in their
composition. Thus, the MS with 69% CB (BLS100
and BLS45) absorbed more STF (51.7 ± 1.7 and
48.3 ± 1.7 l/mg, respectively) than the MS with
41.5% CB (BSLS100 and BSLS45, 23.3 ± 0 and
20.0 ± 0 l/mg, respectively). From these data it is
possible to conclude that the type of lecithin did not
significantly affect the swelling of MS. If we take
into consideration the swelling of BLS100 empty
MS in which the proportion of CB is 75% and the
volume of fluid absorbed 68.3 ± 1.7 l/mg, it is evi-
dent that neither incorporated CsA did not affect the
swelling of MS. Swelling has been proportional to
the CB content (Figure 2).
Thermal properties of MS
Thermal properties of drug and MS were as-
sessed using MDSC. It is well known that reversing
heat flow curves obtained by MDSC are used to de-
tect overlapping thermal events not easily recog-
nised in total heat flow curves (e.g. glass transi-
tions). CsA was originally in an amorphous state as
presented in reversing heat flow curves in Figure 3
that revealed lack of melting peak of crystalline
form. Actually, heat capacity change corresponding
to Tg was evident at 126 °C and correlated well
with already reported data.23,24
The reversing heat flow curves obtained for the
spray-dried MS containing chitosan base, chitosan
chloride or combination thereof, including lecithin
containing MS are presented in Fig 3a-c). All
CsA-loaded chitosan and chitosan/lecithin MS dis-
played fully amorphous nature after spray-drying
process. This preparation process usually produces
amorphous structures as crystallisation process is
prevented due to extremely fast solvent evapora-
tion.
Reversing heat flow curves obtained for
chitosan MS (B, S or BS) have shown no thermal
event attributed to CsA itself, confirming that
spray-drying of single-phase systems resulted in
chitosan MS with CsA dispersed in a polymer ma-
trix.
Moreover, reversing heat flow curves obtained
for chitosan/lecithin MS prepared with chitosan
base and chitosan chloride (Fig 3a-b) also have
shown no thermal event attributed to CsA. This ob-
servation suggests that CsA was evenly dispersed
within lecithin/chitosan ionic complex. In contrary
to that, weak glass transition (being ascribed to
CsA) is observed when combination of chitosan
base and chloride was used regardless of lecithin
type. It is assumed that having four different com-
ponents in a mixture, makes uniform mixing less
feasible resulting in apparent phase separation.
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F i g . 2 – The correlation between swelling properties of
microspheres (expressed as volume of STF absorbed per milli-
gram of microspheres in 15 min swelling process) and chitosan
base content in preparation. Values are mean ± SD (n=3).
Physical mixtures of exact weight proportions
of chitosan, lecithin and CsA were used to confirm
capability of applied methodology to detect CsA re-
lated glass transition (data not shown). Thermal
event appearing at temperature between 95–100 °C
was characteristic for all chitosan samples and was
unaffected by MS composition. Additional study is
needed to understand origin of this thermal event as
published data suggest that glass transition temper-
ature of chitosan is expected in the region between
130–220 °C (being dependant on deacetylation, ori-
gin, molecular weight).25
The release of CsA from MS
In vitro release of active substances from the
drug delivery systems is carried out under condi-
tions similar to in vivo conditions, to predict the re-
lease behaviour in vivo. In vitro dissolution can be
carried out in conditions independent of the in vivo
conditions if aimed to compare the formulations or
find out the release mechanism.26 In this work, the
release study of CsA from MS was conducted in
20 ml of STF (pH = 6.8), at 37 °C while stirring
with a magnetic stirrer (600 rpm). The selected re-
lease media corresponded to ophthalmic conditions,
while the other terms of the in vitro release model
used were independent of the in vivo ocular condi-
tions. The aim of such tests was to compare the pre-
pared MS and to determine the effect of lecithin
and chitosan type on the release of CsA from the
prepared MS.
The release profiles of CsA from conventional
MS prepared with chitosan base, chitosan chloride
or their mixture are shown in Figure 4. For all three
types of chitosan MS a biphasic release profile of
the drug was observed, the initial rapid release fol-
lowed by a slower phase of release. During the
six-hour release test between 83.4 and 92.7% of en-
trapped CsA was released from MS. The observed
CsA release profiles could be attributed to the CsA
location within MS. The first phase of the release
might be driven by dissolution and passive diffu-
sion of CsA located at or near the MS surface. The
second phase may present the release of CsA incor-
porated into the core of the MS or lecithin
nanoparticles.
Thus, for example, the MS prepared with
chitosan base, chitosan chloride or their mixture
in the first 5 minutes released 27.3 ± 6.8%,
45.6 ± 1.5% and 34.0 ± 1.1% incorporated CsA, re-
spectively (Figure 3). These results are consistent
with results obtained by swelling studies of
chitosan MS. Specifically, it was assumed that the
absence of swelling and/or dissolution of chitosan
MS resulted from the presence of lipophilic CsA on
the surface of the MS, which prevented chitosan
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F i g . 3 – The reversing heat flow curves of CsA itself and
CsA-loaded chitosan/lecithin MS where chitosan type is a)
chitosan base (CB), b) chitosan chloride (CS) and c) combina-
tion of chitosan base and chitosan chloride (CB+CS) in the
weight ratio of 3:2.
contact with the aqueous media. Though, incorpo-
ration of CsA in chitosan MS favoured its dissolu-
tion. Specifically, under conditions that were used
for in vitro release, within the six-hour examination
of the dissolution of CsA (equal amounts as en-
trapped in MS) only 51.7 ± 3.0 % of CsA dissolved,
which is significantly less than the amount of CsA
released from the MS in the same study period
(83.4 to 92.7%).
Compared with the release of CsA from con-
ventional chitosan MS prepared with chitosan base
(B) or chitosan chloride (S), the release of CsA
from MS prepared with the mixture of these two
types of chitosan (BS) was better controlled (Figure
3c). After a rapid initial release of CsA from BS
MS, the phase of a uniform release of CsA was ob-
served that corresponded to the zero-order kinetics.
The same pattern was observed for CsA release
from composed chitosan/lecithin MS prepared with
chitosan base (Figure 4a). These observations may
be explained by the better CsA encapsulation due to
the introduction of lecithin in the composition of
MS. There was no significant difference in the re-
lease of CsA with respect to the type of lecithin
used in the preparation of MS . The uniform release
of CsA from the MS can be attributed to emerging
chitosan gel in the process of swelling, which is
a diffusion barrier in the release of CsA and/or
CsA-loaded lecithin nanoparticles.27,28
The literature describes the preparation of simi-
lar drug delivery microsystems in which the
drug-loaded nanoparticles were incorporated into
the polymer matrix, and release of nanoparticles
and/or drug depended on the swelling and/or degra-
dation of the polymer carrier. Thus, for instance,
liposomes were embedded into dextran MS. The re-
lease of liposomes was controlled by dextran matrix
degradation.29 Liposomes were encapsulated into
microspheres of biodegradable polymers by the sol-
vent extraction/evaporation process to form LIMs.30
Before incorporation into the MS, liposomes were
coated with chitosan to improve their stability. The
release of liposomes depended on the size of the
pores of the polymer matrix and the size of the
liposomes. El-Sherbiny and Smyth31 incorporated
polyethylene glycol modified chitosan nanoparticles
into alginate MS. The developed nano-/micro-
spheres carrier systems were formed via spray dry-
ing followed by ionotropic crosslinking in mild
aqueous medium. The release of drug embedded
(bovine serum albumin, BSA) from the MS was
controlled by the swelling of alginate.
The release profiles of CsA from MS obtained
by spray-drying of the single and two-phase sys-
tems composed with chitosan chloride are shown
in Figure 4b. Unlike CsA-loaded conventional
chitosan MS, CsA-loaded composed chitosan/leci-
thin MS dissolved within 5 minutes and released
CsA-loaded nanoparticles immediately. The results
of swelling test showed that conventional MS pre-
pared with chitosan chloride in contact with aque-
ous media remained unchanged while composed
MS prepared with chitosan chloride dissolved at the
same conditions, which is the cause of the immedi-
ate release of CsA-loaded nanoparticles in aqueous
medium.
Complete and high CsA release was obtained
from the conventional MS prepared with chitosan
chloride, although they have not swelled in water.
Up to 50% embedded CsA released in the first
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F i g . 4 – The release profiles of CsA from chitosan (),
chitosan/LS100 () and chitosan/LS45 microspheres () pre-
pared with chitosan base (a), chitosan chloride (b) and their
mixture in the weight ratio of 3:2 (c). The dissolution profile of
CsA () obtained under the conditions applied in the release
studies (STF, pH 6,8; 37°C) has also been included. Values are
mean ± SD (n=3).
5 minutes, the rest released slowly over 6 hours
(Figure 4b).
The literature describes the preparation of simi-
lar nanoparticle microcarrier systems that can easily
dissolve or disperse in contact with water and re-
lease the nanoparticle complexes. Carriers in such
systems can be sugars, e.g. mannitol and lactose,
as well as Aerosil and silica. Thus, for example,
Grenha32 and colleagues used mannitol as micro-
carrier of chitosan/TPP and phospholipids nano-
particles (L/CS-NP) with insulin intended for pul-
monary application. After resuspension and disso-
lution of mannitol microparticles, nanoparticles
were liberated unchanged in size and release profile
of insulin. Sham33 and colleagues examined the sys-
tems in which the carrier of PBCA- gelatin nano-
particles was lactose. In contact with moist of lung
epithelium lactose carrier dissolved, and liberated
nanoparticles. Amorim34 and colleagues used
spray-drying method for incorporation of chitosan
and N-carboxymethyl chitosan nanoparticles with
idebenone in a silica matrix, and thus prepared drug
delivery system suitable for topical or nasal
idebenone aplication. The nanoparticles showed a
10-fold increase of drug stability in comparison
with free drug and preserved antioxidant activity in
vitro.
Release profiles of CsA from MS prepared
with the mixture of chitosan base and chitosan
chloride (3:2, w/w) are shown in Fig 4c. Compared
with the release of CsA from conventional chitosan
MS, the release of CsA from composed chito-
san/lecithin MS was significantly slower and less
consistent. Rapid initial release of CsA from
chitosan/lecithin MS prepared with LS100 and
LS45 (18% and 27% respectively) was followed by
the slow release phase, and the amount of CsA re-
leased soon reached a plateau with maximum of
60% and 70%, respectively. Since chitosan chloride
is freely soluble in water, one would expect that
CB+CS MS would swell well in aqueous medium,
enhancing CsA release like chitosan salt MS with
reduced burst release. It seems however that denser
chitosan matrix/gel was formed that sustained CsA
release from CB+CS MS.
This is corroborated by the fact that the com-
posed chitosan/lecithin MS prepared with the mix-
ture of chitosan base and chitosan chloride (3:2,
w/w) showed a slower release of CsA than the cor-
responding composed MS prepared with chitosan
base only (Figure 4). It can be concluded that the
release rate depended on the MS swelling ability.
The MS, which consisted of chitosan base only ,
swelled better than the MS prepared with CB+CS
mixture.
Conclusions
Spray-dried dispersion formulations of CsA us-
ing chitosan/lecithin as matrix were developed and
characterized. Developed MS revealed great en-
hancement in dissolution rate of CsA especially
those prepared with chitosan chloride. The dissolu-
tion improvement was due to hydrophylisation of
cyclosporine. Developed MS formulations revealed
dissolution profiles that implied that CsA was em-
bedded in a solid dispersion as confirmed by
physicochemical characterization studies and hence
might increase its bioavailability.
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